Other examples relevant to TEs include the CHL1 gene, which based on previous studies exhibits > 0.8 specificity and 0.9 sensitivity in distinguishing IPF patients from healthy controls, meaning that it is a potential IPF drug target [55]. This evidence concerns the gene CHL1 and idiopathic pulmonary fibrosis.